Tofisopam structure
|
Common Name | Tofisopam | ||
---|---|---|---|---|
CAS Number | 22345-47-7 | Molecular Weight | 565.593 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 479.0±45.0 °C at 760 mmHg | |
Molecular Formula | C18H39N5O13S | Melting Point | 155-159ºC | |
MSDS | USA | Flash Point | 195.2±21.2 °C | |
Symbol |
GHS07, GHS09 |
Signal Word | Warning |
Use of TofisopamTofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent[1]. |
Name | 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine |
---|---|
Synonym | More Synonyms |
Description | Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent[1]. |
---|---|
Related Catalog | |
In Vitro | Tofisopam administration at a dose of 50 mg/kg for seven days improves the impaired cognitive performance, enhances the attenuated synaptic transmission in the hippocampus, increases proliferation in subgranular zones, and improves the decrease in astrocytes in amnesic rats[1]. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 479.0±45.0 °C at 760 mmHg |
Melting Point | 155-159ºC |
Molecular Formula | C18H39N5O13S |
Molecular Weight | 565.593 |
Flash Point | 195.2±21.2 °C |
Exact Mass | 565.226501 |
PSA | 61.64000 |
LogP | 2.39 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.558 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07, GHS09 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H400 |
Precautionary Statements | P273 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn: Harmful;N: Dangerous for the environment; |
Risk Phrases | R22;R50 |
Safety Phrases | 60-61 |
RIDADR | UN 3077 |
WGK Germany | 2 |
RTECS | DE9540000 |
Packaging Group | III |
Hazard Class | 6.1(b) |
~60% Tofisopam CAS#:22345-47-7 |
Literature: Gatta; Piazza; Del Giudice; Massotti Farmaco, Edizione Scientifica, 1985 , vol. 40, # 12 p. 942 - 955 |
~95% Tofisopam CAS#:22345-47-7 |
Literature: Vela Pharmaceuticals, Inc. Patent: US2006/264421 A1, 2006 ; Location in patent: Page/Page column 3 ; |
~% Tofisopam CAS#:22345-47-7 |
Literature: US2006/264421 A1, ; Page/Page column 2 ; |
~% Tofisopam CAS#:22345-47-7 |
Literature: Farmaco, Edizione Scientifica, , vol. 40, # 12 p. 942 - 955 |
~% Tofisopam CAS#:22345-47-7 |
Literature: Farmaco, Edizione Scientifica, , vol. 40, # 12 p. 942 - 955 |
~% Tofisopam CAS#:22345-47-7 |
Literature: Farmaco, Edizione Scientifica, , vol. 40, # 12 p. 942 - 955 |
~% Tofisopam CAS#:22345-47-7 |
Literature: Heterocycles, , vol. 88, # 1 p. 287 - 295 |
~% Tofisopam CAS#:22345-47-7 |
Literature: Heterocycles, , vol. 88, # 1 p. 287 - 295 |
The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.
J. Neural Transm. Gen. Sect. 117(11) , 1319-25, (2010) Tofisopam is a member of the 2,3-benzodiazepine compound family which is marketed for the treatment of anxiety in some European countries. In contrast to classical 1,4-benzodiazepines, the compound do... |
|
[Pineal hormone melatonin in low doses potentiates psychotropic and chronotropic activity of tofisopam in rats].
Eksp. Klin. Farmakol. 76(4) , 15-7, (2013) Combination with a low dose of pineal hormone melatonin increased the anxiolytic effect of tofisopam (subthreshold dose) in open-field and cross-maze tests, as well as its chronotropic activity in tim... |
|
Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
Aliment. Pharmacol. Ther. 27(2) , 197-206, (2008) Dextofisopam modulates stimulated activity in animal models of stress, altered bowel motility, and visceral hypersensitivity.To evaluate the effects of dextofisopam in men and women with diarrhoea-pre... |
MFCD00823171 |
1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine |
1-(3,4-dimethoxy-phenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine |
(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminométhyl)-5-hydroxytétrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxyméthyl)tétrahydro-2H-pyran |
(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol sulfate (salt) |
Tobra Gobens |
Tomycin |
5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl- |
5-aethyl-1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-4-methyl-5H-benzodiazepin |
(1S,2S,3R,4S,6R)-4,6-Diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-α-D-glucopyranoside sulfate (salt) |
Dicon |
Egyt 341 |
EINECS 244-922-3 |
(1S,2S,3R,4S,6R)-4,6-Diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-α-D-glucopyranoside sulfate (1:1) |
Dartobcin |
Tofisopamum [INN-Latin] |
Tobracin |
Tofisopam [INN:DCF:JAN] |
Emandaxin |
Nebcine |
UNII:UZC80HAU42 |
Obracin |
Tobraneg |
7,8-dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine |
-3,5-diol sulfate (salt) |
-3,5-diolsulfat(salt) |
(2S,3R,4S,5S,6R)-4-amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminométhyl)-5-hydroxytétrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxyméthyl)tétrahydro-2H-pyran-3,5-diol sulfate (salt) |
Tobrasix |
Grandaxin |
1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine |
Tofisopam |
1-(3,4-dimethoxyphenyl)-7,8-dimethoxy-5-ethyl-4-methyl-5H-2,3-benzodiazepine |
α-D-Glucopyranoside, (1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-, sulfate (1:1) (salt) |
7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine,EGYT 341,Seriel |
Trazil |
tofizopam |
Tobryne |
(2S,3R,4S,5S,6R)-4-Amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran |
Seriel |
(2S,3R,4S,5S,6R)-4-Amino-2-{[(1S,2S,3R,4S,6R)-4,6-diamino-3-{[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-6-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diolsulfat(salt) |